BioCentury | Aug 5, 2019
Company News
Aug. 5 Company Quick Takes: Briefing docs for Descovy cast doubt on full PrEP approval; plus Alnylam, Provention and more
...repurposed to treat cancer. Financial terms are undisclosed. Neuropore in target discovery deal with BenevolentAI Neuropore Therapies Inc....
...emtricitabine/tenofovir alafenamide (Generic), F/TAF (Informal), Descovy (Other) givosiran (ALN-AS1) teplizumab (MGA031, PRV-031) Alnylam Pharmaceuticals Inc. BenevolentAI Cures Within Reach Gilead Sciences Inc. Neuropore Therapies Inc. Provention...
...emtricitabine/tenofovir alafenamide (Generic), F/TAF (Informal), Descovy (Other) givosiran (ALN-AS1) teplizumab (MGA031, PRV-031) Alnylam Pharmaceuticals Inc. BenevolentAI Cures Within Reach Gilead Sciences Inc. Neuropore Therapies Inc. Provention...
